We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Canada to Establish “Big Data” Cloud-Computing Facility for Cancer Research

By LabMedica International staff writers
Posted on 19 May 2014
The Government of Canada announced CAD 7.3 million in funding for a collaboration—both in Canada and internationally—to develop tools that can effectively manipulate huge amounts of data to help find cures for cancer. More...


Recently developed technologies for genetic analysis have created almost unimaginable amounts of data, measured in petabytes. Genomic researchers are eager to analyze these data and identify genetic clues that could point to new ways to prevent or cure cancer. Such an effort, however, requires thousands of high-performance computers working in tandem, along with the yet-unavailable software tools that can coordinate such an intimidating and complex task.

Funded through Canada’s Natural Sciences and Engineering Research Council of Canada’s (NSERC; Ottawa, ON, Canada) Discovery Frontiers, the new project will develop effective new computing tools, so that researchers can study genetic data from thousands of cancers to learn more about how tumors develop, and which treatments work best.

At the center of the project will be a new cloud-computing facility, the Cancer Genome Collaboratory (Ottawa, ON, Canada), capable of processing genetic profiles gathered by the International Cancer Genome Consortium (ICGC) from tumors in some 25,000 patients worldwide. The powerful new data-mining tools are expected to be available in 2015 for beta testing by selected cancer genomics and privacy researchers. The facility is planned to be opened to the wider research community in 2016. Researchers will be able to formulate questions about cancer risk, tumor growth, and drug treatments, and extract an analysis against the data.

The NSERC initiated the project with a partnership among federal granting organizations that also include Genome Canada, the Canada Foundation for Innovation (CFI), and the Canadian Institutes of Health Research (CIHR).

The University of Chicago (IL, USA) is also providing critical computing resources for the project. Furthermore, a large initial donation of genomic data will come from the International Cancer Genome Consortium, and brings together researchers from some 16 jurisdictions worldwide. The International Cancer Genome Consortium is the largest worldwide coordinated effort to produce a catalog of genetic structure of cancer organisms. Its 10-year goal is to characterize the genetic materials from tumors in 500 patients for each of the major cancer types.

“Our government is making record investments in science and technology to create jobs, strengthen the economy and improve the quality of life of Canadians. Our investment in this new powerful, state of the art tool will allow Canadian and international researchers to greatly advance our understanding of the causes of cancer,” stated Ed Holder, Canadian Minister of State (Science and Technology).

“Canada and many other nations around the world have already invested tremendous resources in sequencing of thousands of cancer genomes, but until now there has been no viable long-term plan for storing the raw sequencing data in a form that can be easily accessed by the research community. The Cancer Genome ‘Collaboratory’ will open this incredibly important data set to researchers from laboratories large and small, enabling them to achieve new insights into the causes of cancer and to develop innovative new ways to diagnose and manage the disease,” noted Lincoln Stein, director, Informatics and Biocomputing Program, Ontario Institute for Cancer Research, and professor, department of molecular genetics, University of Toronto (Canada).

Related Links:

International Cancer Genome Consortium
Natural Sciences and Engineering Research Council



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.